Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Linafexor in Hepatic Impairment
NCT06888115Phase 1Completed
- Sponsor
- Cascade Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of linafexor in primary biliary cholangitis (PBC) (3 arms), sponsored by Cascade Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to last measurable concentration and 6 more. Started Mar 2025; status: completed.
02
Drugs
linafexor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06888115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888115.